Login to Your Account

Pharma: Clinic Roundup

Tuesday, May 8, 2012
• Galleon Pharmaceuticals Inc., of Horsham, Pa., said its drug candidate GAL-021 was safe and well tolerated in a Phase I trial in 30 healthy adults. The company is investigating GAL-021 for improving breathing in patients receiving opioids, which are known to depress the respiratory system.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription